Pep IQ
← Pep IQ
Cerebrolysin is a multi-component preparation derived from purified porcine brain tissue containing low-molecular-weight peptides (15% by content) and free amino acids (85%) — each mL of solution contains 215.2 mg of Cerebrolysin peptide concentrate plus 2.1 mg sodium hydroxide. Animal models show neurotrophic effects (BDNF/NGF-like activity), neuroprotection in ischaemia models, and modulation of PI3K/AKT, GSK3β and Sonic hedgehog signalling pathways — the latter is currently discussed as a pivotal pathway for blood-brain barrier integrity and post-stroke neuroprotection. Unlike single-peptide compounds where one molecule has one mechanism, Cerebrolysin's multi-component composition produces a 'pleiotropic' effect that has been simultaneously its mechanistic strength and its regulatory weakness in Western markets.
Community use mirrors the clinical protocol — typical doses by indication (mL converted to mg using the 215.2 mg/mL concentration): 5 mL IM (~1,076 mg) daily for mild cognitive support; 10 mL IM (~2,152 mg) for moderate cognitive or recovery use; 20 mL IV (~4,304 mg) for vascular dementia; 30 mL IV (~6,456 mg) for acute stroke and TBI under clinical supervision. Course length 10–21 days, repeated every 2–3 months. Continuous daily use is not how this is used — defined courses with rest periods is the established pattern. Self-administration via IM is feasible at lower doses; IV (which is how the major trials dosed) requires clinical setting. Volume-equivalent dosing matters because porcine-brain peptide concentrate is sold as a fixed-concentration solution rather than reconstituted from lyophilised powder — the mg dose equals (mL × 215.2).
Substantial Phase 3/4 evidence base. CARS trial (Stroke 2015, Pubmed 26564102) — 30 mL/day (~6,456 mg/day) IV for 21 days starting 24–72h post-stroke, paired with rehabilitation, large superiority on Action Research Arm Test at day 90 (Mann-Whitney 0.71). CASTA Phase 4 (NCT00868283) — 30 mL/day IV for 10 consecutive days in acute ischaemic stroke. Vascular dementia trial (NCT00947531) — 20 mL/day (~4,304 mg/day) IV for two 4-week courses with 2-month interval, ADAS-cog+ and CIBIC+ endpoints; 242-patient multicentre RCT (Guekht et al. 2011, Pubmed 20656516) showed combined cognition and clinical-functioning improvement at 24 weeks. Alzheimer's trial (NCT00911807, Combi study) — 10 mL Cerebrolysin (~2,152 mg) IV vs Aricept 10 mg vs combination, 5×/week for 4 weeks, repeated. Alvarez et al. 2006 24-week trial tested three Cerebrolysin doses in mild-to-moderate Alzheimer's. Meta-analysis of 9 RCTs showed Cerebrolysin doses of 30–50 mL (~6,456–10,760 mg) over 10–21 days significantly outperformed placebo. Cognitive Vitality (Alzheimer's Drug Discovery Foundation) review noted the 30 mL/day dose for 4 weeks produced positive results, and that higher doses may be less effective. Cochrane 2019 vascular dementia review found beneficial cognitive effect (SMD 0.36) but rated evidence quality as very low due to industry funding and methodology variability. The 2012 CASTA stroke trial cast doubts on routine use in mild/moderate acute stroke, with post-hoc analysis suggesting benefit concentrated in severe stroke (NIHSS >12).
Approved in 50+ countries including Russia, China, Mexico, Austria, Romania, and many CIS and Asian markets. Manufactured by EVER Neuro Pharma (Austria) to pharmaceutical-grade standards. Not FDA-approved, not EMA-approved, not MHRA-approved. The 2021 EAN/EFNR European Academy of Neurology guidelines recommend Cerebrolysin 30 mL/day (~6,456 mg/day) IV for at least 10 days as a pharmacological adjunct to early motor rehabilitation post-stroke — so the regulatory picture is split, with European neurology bodies endorsing specific protocols even though EMA has not registered the compound. Long safety record across decades of clinical use in approved markets. Sourcing in Western markets is via off-label clinical channels or research vendors with associated quality concerns.
Cerebrolysin has one of the strongest clinical evidence bases of any neuropeptide preparation — CARS, CASTA, multiple dementia RCTs, Cochrane reviews, and EAN/EFNR guideline endorsement for stroke rehabilitation. Standard validated protocol: 30 mL/day (~6,456 mg/day) IV for 10–21 days for stroke; 20 mL/day (~4,304 mg/day) IV for vascular dementia; 10 mL/day (~2,152 mg/day) for chronic Alzheimer's protocols, all repeated as defined courses with 2–3 month intervals. Pep IQ flags this honestly: legitimate compound with real Phase 3/4 evidence in approved indications, but the FDA/EMA non-approval reflects regulatory pathway decisions rather than safety or efficacy concerns — and the Cochrane very-low-quality-evidence rating for vascular dementia is a real caveat. Strongest evidence sits in stroke rehabilitation and vascular dementia; weakest evidence is in cognitive enhancement for healthy individuals (no trials were designed for that use case).
Cerebrolysin occupies one of the most paradoxical positions in neuropharmacology. It has more clinical trial data than any other cognitive compound in this book — approved in over 50 countries across Europe and Asia for stroke, traumatic brain injury, and dementia — and has been used clinically for decades. It is manufactured by Ever Neuro Pharma in Austria to pharmaceutical standards.
And yet it is not available in the United States. Not because it was found to be ineffective or dangerous — but because the FDA's approval pathway requires the specific trial design and statistical standards that Cerebrolysin's existing trials (mostly European and Asian) did not fully meet by US standards, and no company has invested in running a full FDA trial package.
This creates a situation where a drug approved by regulatory bodies across 50 countries and backed by multiple RCTs and Cochrane reviews is simultaneously unavailable through legitimate US channels and obtainable through grey-market sources — where quality and dosing accuracy cannot be verified.
Cerebrolysin is not a single synthetic peptide — it's a complex mixture produced by standardised enzymatic hydrolysis of purified porcine brain proteins. The result is a preparation containing low molecular weight peptide fragments and free amino acids from multiple neurotrophic factors. This is both its strength (broad multi-target activity) and its regulatory challenge (variable composition, difficult to characterise precisely).
The critical delivery constraint: oral Cerebrolysin is essentially useless. Peptides are broken down in the gut before reaching systemic circulation. Clinical doses of 30ml/day are administered intravenously. This is why the compound is impractical for widespread use despite its clinical evidence — it requires supervised IV administration, cannot be self-dosed as a nasal spray or injection, and the biohacker community obtaining it through grey channels faces significant barriers to replicating clinical dosing conditions.